CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.3735 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 91.75% |
Profile
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist). |
URL | https://www.cymabay.com |
Investor Relations URL | https://www.cymabay.com/investors-media |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Mar. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist). |
URL | https://www.cymabay.com |
Investor Relations URL | https://www.cymabay.com/investors-media |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Mar. 15, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |